

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: James Martin Lenhard

Serial No.: To be assigned

Filed: Concurrently herewith

For: METHODS OF SCREENING PROTEASE INHIBITORS, OF INDUCING MICE SUSCEPTIBLE TO HIV PROTEASE INHIBITOR-INDUCED DYSLIPIDEMIA, AND GENES ASSOCIATED THEREWITH

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

[ ] Copies of the references are enclosed

[ ] Copies of the references were submitted in parent application Serial No. \_\_\_\_\_ (37 CFR 1.98(d))

[ X ] A copy of the International Search Report which issued on International Application No. PCT/US00/01205 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449. (37 CFR 1.98(d)), and applicants understand that copies have been supplied to the USPTO by the International Bureau.

A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

B. [ ] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

[ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

[ ] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$200.00).

C. [ ] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.

09/889471

Docket No. PU3610USW

JC03 Rec'd PCT/PTL


17 JUL 2001

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- Please charge required fees to Deposit Account No. 07-1392.
- A duplicate copy of this paper is attached.

Date: 17 July 2001

Respectfully Submitted,


  
Elizabeth Selby  
Attorney of Record, Reg. No. 38,298

GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
(919) 483-3934

CERTIFICATE OF EXPRESS MAILING (37 CFR 1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Assistant Commissioner of Patents and Trademarks, Washington, D.C. 20231 on

Date: 17 July 2001

  
Marilyn Eldridge

